Merck KGaA Drops Cancer Drug Development After Studies Fail

By
Anjali Cordeiro
and
Johannes Koch
  • Patients didn't live longer when taking evofosfamide in tests
  • Partner Threshold's stock slides 70% in pre-market trading

German drugmaker Merck KGaA said it won’t seek regulatory approval for its experimental cancer medicine evofosfamide after the treatment failed in the last stage of clinical tests.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.

Read this article on the Terminal Request a demo to learn more

You might like:
  1. Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
  2. Trump Boosts North Korea Sanctions, Adding Economic Pressure
  3. Mercedes Plots Tesla Attack With $1 Billion U.S. Electric Push
  4. Home Prices Soar in Disaster-Prone Areas
  5. Ronaldo Is Hawking One of the World’s Riskiest Derivatives